Thought Leadership
U.S. Support for Patent Waiver Unlikely to Cost Covid-19 Vaccine Makers in Short Term
May 7, 2021
Jared Hopkins
The Wall Street Journal

Axinn partner David Silverstein was quoted in The Wall Street Journal article, "U.S. Support for Patent Waiver Unlikely to Cost Covid-19 Vaccine Makers in Short Term."

Click here to access the article. A subscription is required. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.